Epilepsy treatment now available as licensed medicine

Epistatus (midazolam), previously classified as an unlicensed special, has been granted a UK marketing authorisation and is now available to prescribe as a licensed medicine for children with epilepsy.

Midazolam is a schedule 3 controlled drug and prescriptions for it should comply with CD requirements. | VERITON PHARMA
Midazolam is a schedule 3 controlled drug and prescriptions for it should comply with CD requirements. | VERITON PHARMA

Epistatus, an oromucosal solution containing 10mg/ml midazolam, is licensed for the treatment of prolonged, acute, convulsive seizures in children and adolescents aged 10 to less than 18 years, who have been diagnosed with epilepsy. 

Epistatus has been formulated for buccal administration and is presented in a ‘ready-to-use’, pre-filled, single-dose oral syringe to facilitate administration of the correct dose. 

NICE recommends buccal midazolam as first-line treatment in children, young people and adults with prolonged or repeated convulsive seizures. 

'The importance of having an alternate licensed preparation for use in the treatment of prolonged, acute convulsive seizures, especially in a different mode of delivery, is an asset to both clinicians and patients', said Dr Rohit Shankar, consultant in adult developmental neuropsychiatry at the Cornwall Partnership NHS Foundation Trust. 

The alternative buccal midazolam preparation Buccolam is licensed for use in children from 3 months to less than 18 years.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New antibiotic prescribing guidance issued for pneumonia

New antibiotic prescribing guidance issued for pneumonia

NICE has published antimicrobial prescribing guidelines...

MIMS summary of NICE COPD guidance updated

MIMS summary of NICE COPD guidance updated

Prescribers can now consult the quick-reference MIMS...

Soft-mist inhaler now available as reusable device

Soft-mist inhaler now available as reusable device

Respimat is now available as a reusable inhaler that...

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...